<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Novo Nordisk A/S (NYSE:NVO) shares traded higher by 3.2% on Thursday morning after the insulin and diabetes care leader landed a major Wall Street upgrade. The Analyst: Bank of America analyst Sachin Jain upgraded Novo Nordisk from Neutral to Buy and raised his price target from $100.27 to $117.04.
...read full article on Benzinga
